Shree Jaya Laboratories was certified for ISO 9001-2008 during the year 2010. SJL have been exporting their products to countries like China and Spain after successfully established in the domestic market by meeting customer requirements with excellent quality and timely supply.

Shree Jaya had developed bulk drugs and drug intermediates in their Research & Development department which include Omeprazole, Pentaprazole, Domperidone, Esomeprazole, Loratidine, Citlopram etc., derivatives.

The manufacturing facility of SJL is well equipped with necessary infrastructure required for the manufacture of Active Pharma Ingredients and Drug Intermediates. SJL is committed to provide Safety to its employees by providing necessary safety appliances along with required training. SJL meticulously follow the guidelines provided by pollution control board and protect the environment by installing pollution control equipment.

Shree Jaya Laboratories was established in the year 2005with the aim of offering commercial, technical and scientific support to pharmaceutical industries. SJL developed a strong Technical Team to manufacture and supply Drug Intermediates and Active Pharma Ingredients to domestic as well as international markets. SJL started its bulk business in the year 2006 with the manufacture of derivatives of Pentaprozole, Piperidone, Piperidine and Omeprazole.

Shree Jaya Laboratories now put their focus on the high-tech molecules for both regulatory and non-regulatory markets of USA, Canada & Europe.

Well equipped R&D Laboratory with qualified and skilled personnel could commercialize the multi step synthetic products like Domperidone, Loperamide HCl, Omeprazole & Pentaprazole etc.,

The manufacturing facility at SJL had six well equipped production blocks. One of the production blocks is dedicatedly being used for corrosive reactions. The facility had well equipped clean room to produce drug intermediates.

SJL also offers their dedicated equipment and facilities for the manufacture of Active Pharma Ingredients and Drug Intermediates as per cGMP requirements.